文献速递类风湿关节炎

类风湿关节炎中以缓解还是低疾病活动度作为治疗目标:如何在过严与过宽目标之间取得恰当平衡?一项基于个体患者数据的荟萃流行病学研究

Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data.
PubMed 文献 · RMD Open · 2024-11-07

该荟萃流行病学研究基于8项随机对照试验的个体患者数据(共4374例),比较以SDAI-LDA(SDAI≤11)与三种缓解定义(SDAI缓解≤3.3、4V缓解、3V缓解)作为治疗目标时2年影像学进展的差异。结果显示SDAI-LDA较任何缓解定义均与更多结构损伤相关,且超过53%达到SDAI-LDA者未达3V缓解、影像学进展更多。作者认为医师应尽可能安全地追求缓解。

要点

  • SDAI-LDA目标较任何缓解定义与2年更多结构损伤相关。
  • 达到SDAI-LDA者中超过53%未达3V缓解,其2年影像学进展更多。
  • 在SDAI-LDA但未达SDAI缓解者中,40%的患者整体评估(PGA)>2。

核心结论

  • SDAI-LDA较任何缓解定义与2年更多结构损伤相关,且允许显著疾病影响未被检出和控制。
  • 作者认为医师应尽可能安全地追求缓解,同时考虑所采用定义中的各项个体疾病活动度参数。

研究设计与样本

  • 基于8项随机对照试验个体患者数据的荟萃流行病学研究。
  • 共纳入4374例已确诊类风湿关节炎患者,平均病程5.9年(95%CI 4.6; 7.1)。
  • 在6个月时评估四种治疗目标定义:SDAI-LDA(SDAI≤11)、SDAI缓解(SDAI≤3.3)、4V缓解(28关节压痛和肿胀计数及C反应蛋白(mg/dL)均≤1且患者整体评估(PGA)≤2)、3V缓解(同4V但不包括PGA)。
  • 比较2年内改良总Sharp-van der Heijde评分(mTSS)平均影像学变化及良好影像学结局率(定义为mTSS变化≤0.5单位)。

主要发现

  • 6个月时SDAI-LDA的汇总达标率为49%,SDAI缓解为13%,4V缓解为16%,3V缓解为23%。
  • 2年平均影像学进展:SDAI-LDA为0.55(0.14; 0.96)单位,SDAI缓解为0.22(-0.09; 0.54)单位,4V缓解为0.28(-0.07; 0.62)单位,3V缓解为0.28(-0.10; 0.65)单位。
  • SDAI单纯LDA患者影像学进展显著多于SDAI缓解患者(平均0.72 vs 0.22单位,p<0.05)。
  • 达到SDAI-LDA者中超过53%未达3V缓解,其2年平均影像学进展多于同时达到两目标者(0.70 vs 0.25单位,p=0.014)。
  • 在SDAI-LDA但未达SDAI缓解者中,40%的患者PGA>2,反映相关疾病影响。

关键数值与推荐

  • SDAI-LDA定义:SDAI≤11。
  • SDAI缓解定义:SDAI≤3.3。
  • 4V缓解定义:28关节压痛和肿胀计数及C反应蛋白(mg/dL)均≤1且PGA≤2。
  • 3V缓解定义:同4V但不包括PGA。
  • 良好影像学结局定义:mTSS变化≤0.5单位。

临床怎么用

  • 作者认为医师应尽可能安全地追求缓解,而非以满足SDAI-LDA为目标。
  • 作者认为选择目标时应考虑所采用缓解定义中的各项个体疾病活动度参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the impact of using Simplified Disease Activity Index (SDAI)-LDA (low disease activity) versus different definitions of remission as a treatment target in established rheumatoid arthritis. METHODS: A meta-epidemiological study of individual patient data from eight randomised controlled trials was performed. Four definitions of the target were considered at 6 months: (1) SDAI-LDA: SDAI≤11; (2) SDAI-Remission: SDAI≤3.3; (3) 4V-Remission: Tender and swollen 28-joint counts and C reactive protein (mg/dL) all ≤1 and patient global assessment (PGA)≤2 and (4) 3-variable (3V)-Remission: as 4V, excluding PGA. The mean radiographic change in the modified total Sharp-van der Heijde score (mTSS) and the Good Radiographic Outcome rates (defined as a change of ≤0.5 units mTSS) over 2 years were compared among target definitions. Radiographic progression and the distribution of the individual criteria of the Boolean definition in the only LDA subgroup (3.3<SDAI≤11) were analysed. RESULTS: In total, 4374 patients (mean disease duration of 5.9 years (95% CI 4.6; 7.1)) were included. The pooled rate of SDAI-LDA at 6 months was 49%, with 13% in SDAI-remission. The 4V-Remission and 3V-Remission were achieved by 16% and 23%, respectively. Mean radiographic progression was 0.55 (0.14; 0.96) units for SDAI-LDA and 0.22 (-0.09; 0.54), 0.28 (-0.07; 0.62), 0.28 (-0.10; 0.65) for SDAI-Remission, 4V-Remission and 3V-Remission states, respectively. Patients with SDAI Pure-LDA presented significantly more radiographic progression than patients in SDAI-Remission (mean 0.72 vs 0.22 units, p<0.05). Over 53% of all patients achieving SDAI-LDA were not in 3V-Remission and had more mean radiographic progression over 2 years than those who met both targets (0.70 vs 0.25 units, p=0.014). Among patients with SDAI-LDA but not in SDAI-Remission, 40% scored PGA>2, reflecting relevant disease impact. CONCLUSION: SDAI-LDA is associated with more structural damage over 2 years than any of the definitions of remission. It also allows substantial disease impact to go unchecked and uncontrolled. Physicians should strive for remission whenever possible and safe while also taking into account the different individual disease activity parameters included in the adopted definition.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Duarte C, Jacobs JWG, Ferreira RJO, et al. Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data. RMD Open. 2024. PMID: 39516011. doi:10.1136/rmdopen-2024-004387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。